vs

Side-by-side financial comparison of PTC THERAPEUTICS, INC. (PTCT) and WisdomTree, Inc. (WT). Click either name above to swap in a different company.

PTC THERAPEUTICS, INC. is the larger business by last-quarter revenue ($164.7M vs $159.5M, roughly 1.0× WisdomTree, Inc.). WisdomTree, Inc. runs the higher net margin — 25.5% vs -82.0%, a 107.4% gap on every dollar of revenue. On growth, WisdomTree, Inc. posted the faster year-over-year revenue change (47.5% vs -22.7%). Over the past eight quarters, WisdomTree, Inc.'s revenue compounded faster (22.1% CAGR vs -11.5%).

PTC Therapeutics, Inc. is a US pharmaceutical company focused on the development of orally administered small molecule drugs and gene therapy which regulate gene expression by targeting post-transcriptional control (PTC) mechanisms in orphan diseases.

WisdomTree, Inc. is a global exchange-traded fund (ETF) and exchange-traded product (ETP) sponsor and asset manager with headquarters in New York. WisdomTree launched its first ETFs in June 2006, and became one of the major ETF providers in the United States. WisdomTree sponsors different ETFs that span asset classes and countries worldwide. Categories include: U.S. and International Equity, Currency, Fixed Income and Alternatives.

PTCT vs WT — Head-to-Head

Bigger by revenue
PTCT
PTCT
1.0× larger
PTCT
$164.7M
$159.5M
WT
Growing faster (revenue YoY)
WT
WT
+70.3% gap
WT
47.5%
-22.7%
PTCT
Higher net margin
WT
WT
107.4% more per $
WT
25.5%
-82.0%
PTCT
Faster 2-yr revenue CAGR
WT
WT
Annualised
WT
22.1%
-11.5%
PTCT

Income Statement — Q4 FY2025 vs Q1 FY2026

Metric
PTCT
PTCT
WT
WT
Revenue
$164.7M
$159.5M
Net Profit
$-135.0M
$40.6M
Gross Margin
Operating Margin
-43.3%
37.2%
Net Margin
-82.0%
25.5%
Revenue YoY
-22.7%
47.5%
Net Profit YoY
-104.8%
76.4%
EPS (diluted)
$-1.63
$0.28

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
PTCT
PTCT
WT
WT
Q1 26
$159.5M
Q4 25
$164.7M
$147.4M
Q3 25
$211.0M
$125.6M
Q2 25
$178.9M
$112.6M
Q1 25
$1.2B
$108.1M
Q4 24
$213.2M
$110.7M
Q3 24
$196.8M
$113.2M
Q2 24
$186.7M
$107.0M
Net Profit
PTCT
PTCT
WT
WT
Q1 26
$40.6M
Q4 25
$-135.0M
$40.0M
Q3 25
$15.9M
$19.7M
Q2 25
$-64.8M
$24.8M
Q1 25
$866.6M
$24.6M
Q4 24
$-65.9M
$27.3M
Q3 24
$-106.7M
$-4.5M
Q2 24
$-99.2M
$21.8M
Operating Margin
PTCT
PTCT
WT
WT
Q1 26
37.2%
Q4 25
-43.3%
40.5%
Q3 25
1.4%
36.3%
Q2 25
-19.5%
30.8%
Q1 25
82.5%
31.6%
Q4 24
-76.2%
31.7%
Q3 24
-27.7%
36.0%
Q2 24
-21.5%
31.3%
Net Margin
PTCT
PTCT
WT
WT
Q1 26
25.5%
Q4 25
-82.0%
27.1%
Q3 25
7.5%
15.7%
Q2 25
-36.3%
22.0%
Q1 25
73.7%
22.8%
Q4 24
-30.9%
24.7%
Q3 24
-54.2%
-4.0%
Q2 24
-53.1%
20.3%
EPS (diluted)
PTCT
PTCT
WT
WT
Q1 26
$0.28
Q4 25
$-1.63
$0.28
Q3 25
$0.20
$0.13
Q2 25
$-0.83
$0.17
Q1 25
$10.04
$0.17
Q4 24
$-0.85
$0.20
Q3 24
$-1.39
$-0.13
Q2 24
$-1.29
$0.13

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
PTCT
PTCT
WT
WT
Cash + ST InvestmentsLiquidity on hand
$1.9B
Total DebtLower is stronger
Stockholders' EquityBook value
$-205.3M
Total Assets
$2.9B
$1.8B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
PTCT
PTCT
WT
WT
Q1 26
Q4 25
$1.9B
Q3 25
$1.7B
Q2 25
$2.0B
Q1 25
$2.0B
Q4 24
$1.1B
Q3 24
$1.0B
Q2 24
$1.1B
$132.5M
Stockholders' Equity
PTCT
PTCT
WT
WT
Q1 26
Q4 25
$-205.3M
$413.7M
Q3 25
$-155.8M
$373.4M
Q2 25
$-206.5M
$445.1M
Q1 25
$-185.8M
$415.6M
Q4 24
$-1.1B
$400.0M
Q3 24
$-1.1B
$374.9M
Q2 24
$-980.2M
$445.6M
Total Assets
PTCT
PTCT
WT
WT
Q1 26
$1.8B
Q4 25
$2.9B
$1.5B
Q3 25
$2.6B
$1.4B
Q2 25
$2.6B
$1.1B
Q1 25
$2.7B
$1.0B
Q4 24
$1.7B
$1.0B
Q3 24
$1.8B
$1.0B
Q2 24
$1.9B
$964.1M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
PTCT
PTCT
WT
WT
Operating Cash FlowLast quarter
$-34.3M
$18.0M
Free Cash FlowOCF − Capex
$-36.6M
FCF MarginFCF / Revenue
-22.3%
Capex IntensityCapex / Revenue
1.4%
Cash ConversionOCF / Net Profit
0.44×
TTM Free Cash FlowTrailing 4 quarters
$702.3M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
PTCT
PTCT
WT
WT
Q1 26
$18.0M
Q4 25
$-34.3M
$147.9M
Q3 25
$-66.3M
$48.1M
Q2 25
$-58.3M
$38.8M
Q1 25
$870.1M
$6.4M
Q4 24
$-30.0M
$113.5M
Q3 24
$-77.0M
$47.7M
Q2 24
$-71.5M
$32.2M
Free Cash Flow
PTCT
PTCT
WT
WT
Q1 26
Q4 25
$-36.6M
$147.7M
Q3 25
$-69.7M
$48.0M
Q2 25
$-59.6M
$38.7M
Q1 25
$868.4M
$6.3M
Q4 24
$-33.8M
$113.3M
Q3 24
$-77.5M
$47.7M
Q2 24
$-78.8M
$32.2M
FCF Margin
PTCT
PTCT
WT
WT
Q1 26
Q4 25
-22.3%
100.2%
Q3 25
-33.1%
38.2%
Q2 25
-33.3%
34.4%
Q1 25
73.8%
5.9%
Q4 24
-15.8%
102.4%
Q3 24
-39.4%
42.1%
Q2 24
-42.2%
30.1%
Capex Intensity
PTCT
PTCT
WT
WT
Q1 26
Q4 25
1.4%
0.1%
Q3 25
1.6%
0.0%
Q2 25
0.7%
0.1%
Q1 25
0.1%
0.0%
Q4 24
1.8%
0.1%
Q3 24
0.3%
0.0%
Q2 24
4.0%
0.0%
Cash Conversion
PTCT
PTCT
WT
WT
Q1 26
0.44×
Q4 25
3.70×
Q3 25
-4.17×
2.44×
Q2 25
1.57×
Q1 25
1.00×
0.26×
Q4 24
4.15×
Q3 24
Q2 24
1.48×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

PTCT
PTCT

Segment breakdown not available.

WT
WT

Advisory fees$134.9M85%
Other$6.1M4%
Third-party distribution fees$5.8M4%
Management fees$5.2M3%
Sales and business development$4.2M3%
Professional fees$3.3M2%

Related Comparisons